既往HBV暴露者皮质类固醇治疗后HBsAg血清学逆转风险
该研究纳入2001-2010年间HBsAg阴性且接受皮质类固醇治疗的患者12997例,评估既往HBV暴露者HBsAg血清学逆转和肝炎发作风险。结果显示仅anti-HBc阳性者1年HBsAg逆转率为1.8%,高于双阴性者的0%;高日剂量皮质类固醇增加肝炎发作风险但不增加血清学逆转风险,肝衰竭发生率低且与未暴露者相似。
要点
- 仅anti-HBc阳性者HBsAg血清学逆转风险高于双阴性者(1年发生率1.8% vs 0%,p=0.014)。
- 泼尼松等效日剂量20-40mg或>40mg且疗程<7天即增加肝炎发作风险。
- 既往HBV暴露者肝衰竭发生率与未暴露者相似,无死亡或肝移植需求。
核心结论
- 在HBsAg阴性且仅anti-HBc阳性的患者中,高日剂量皮质类固醇增加肝炎发作风险,但不增加HBsAg血清学逆转风险。
- 既往HBV暴露者肝衰竭发生率低且与未暴露者相似,无死亡或肝移植需求。
研究设计与样本
- 纳入2001-2010年间HBsAg阴性且接受皮质类固醇治疗的患者共12997例。
- 既往HBV暴露定义为anti-HBs和/或anti-HBc阳性。
- 主要终点为HBsAg血清学逆转,次要终点为1年时肝炎发作(ALT>80 U/L)。
主要发现
- 共165例发生HBsAg血清学逆转。
- 仅anti-HBc阳性者1年HBsAg逆转发生率为1.8%,双阴性者为0%(p=0.014)。
- 既往HBV暴露者与未暴露者肝衰竭发生率分别为1.1%和0.9%。
- 泼尼松等效峰值日剂量20-40mg且疗程<7天时肝炎发作风险aHR 2.19(p=0.048),>40mg时aHR 2.11(p=0.015)。
- 疗程7-28天和>28天时肝炎发作风险aHR 2.02-3.85(p<0.001-0.012)。
临床怎么用
- 开始皮质类固醇治疗前应了解患者HBV状态。
- 对既往HBV暴露者应定期监测肝功能以及早发现肝炎发作。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Systemic corticosteroids may cause HBV reactivation, but the impact on patients with previous HBV exposure is poorly defined. We aimed to study the risk of HBsAg seroreversion and hepatitis flare in patients with previous HBV exposure. METHODS: Patients who were negative for HBsAg and received corticosteroids between 2001-2010 were included. Patients who were positive for antibody to HBsAg (anti-HBs) and/or to HBcAg (anti-HBc) were defined as having previous HBV exposure. The primary endpoint was HBsAg seroreversion; the secondary endpoint was hepatitis flare (alanine aminotransferase >80 U/L) at 1 year. RESULTS: A total of 12,997 patients fulfilled the inclusion criteria: anti-HBs positive only (n = 10,561); anti-HBc positive only (n = 970); anti-HBs & anti-HBc positive (n = 830) and anti-HBs & anti-HBc negative (n = 636). HBsAg seroreversion occurred in 165 patients. Patients who were anti-HBc positive only had a higher risk of HBsAg seroreversion (1-year incidence 1.8%) than those negative for both anti-HBs & anti-HBc (0%; p = 0.014). Patients with previous HBV exposure had a similarly low risk of liver failure as unexposed individuals (1.1% vs. 0.9%). The risk of a hepatitis flare started to increase in those receiving corticosteroids at peak daily doses of 20-40 mg (adjusted hazard ratio [HR] 2.19, p = 0.048) or >40 mg (aHR 2.11, p = 0.015) prednisolone equivalents for <7 days, and was increased at treatment durations of 7-28 days and >28 days (aHR 2.02-3.85; p <0.001-0.012). CONCLUSIONS: In HBsAg-negative patients who were only anti-HBc positive, high peak daily doses of corticosteroids increased the risk of hepatitis flare, but not seroreversion. The rate of liver failure was low and similar in HBV exposed and unexposed individuals; there were no deaths, nor any requirement for liver transplantation. LAY SUMMARY: It is important to know the hepatitis B virus (HBV) status before starting corticosteroid therapy. Patients with resolved HBV infection without detectable immunity are at an increased risk of HBV surface antigen seroreversion after corticosteroid therapy. High peak daily doses of corticosteroids (>40 mg prednisolone equivalents) increase the risk of hepatitis flare, but not seroreversion, in patients with previous exposure to HBV, irrespective of the duration of treatment. Interval monitoring of liver biochemistries is essential for the early detection of hepatitis flares in these patients.
引用
- Wong GL, Wong VW, Yuen BW, et al. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J Hepatol. 2019. PMID: 31499132. doi:10.1016/j.jhep.2019.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。